Drugs / AGX101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06440005 | Jul 2024 → Sep 2026 overdue | angiosarcoma, breast cancer, colorectal cancer, invasive carcinoma +4 | Angiex, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Angiex, Inc. | Results Angiex Reports AACR In Vivo Data Supporting AGX101 in Combination With Immune Checkpoint Inhibitors for Solid Tumors angiex.com ↗
The findings support AGX101 as a promising new approach in cancer therapy and suggest it may provide therapeutic benefit through novel and differentiated mechanisms of action, including selective targeting of the tumor vasculature and potentiation of immuno-oncology therapy. |
| 2023-11-02 | Angiex, Inc. | Regulatory Angiex Announces FDA Clearance of IND Application for AGX101 angiex.com ↗
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Angiex, Inc. | Angiex Reports AACR In Vivo Data Supporting AGX101 in Combination With Immune Checkpoint Inhibitors for Solid Tumors angiex.com ↗ |
| 2025-11-14 | Angiex, Inc. | Angiex Completes $31M Financings for Phase 1 Clinical Development of AGX101 angiex.com ↗ |
| 2024-08-07 | Angiex, Inc. | Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101 angiex.com ↗ |
| 2023-11-02 | Angiex, Inc. | Angiex Announces FDA Clearance of IND Application for AGX101 angiex.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGX101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06440005 ↗ |
| Route | Intravenous | “AGX101will be administered intravenously.” NCT06440005 ↗ |
| Target | TM4SF1 | “AGX101, a TM4SF1 Directed Antibody Drug Conjugate” NCT06440005 ↗ |